BioSpace News Archive

Sofinnova Investments, a clinical stage biopharmaceutical investment firm, announces the promotions of Maha Katabi, PhD, CFA to General Partner and Sarah Bhagat, PhD to Partner.

OutSystems announced that STEMCELL Technologies has launched its “My Status” app to help keep STEMCELL staff safe during the COVID-19 pandemic.

The US Oncology Network (The Network) has named prominent cancer researcher Robert L. Coleman, MD, FACOG, FACS, as its new Chief Scientific Officer.

A new retrospective data analysis published in Kidney Medicine shows that a higher percentage of hemodialysis patients prescribed Velphoro® (sucroferric oxyhydroxide chewable tablets) achieved target serum phosphorous levels of ≤5.5 mg/dL compared to those patients who switched from Velphoro to another phosphate binder.

Quantzig, a global data analytics and advisory firm, that delivers actionable analytics solutions to resolve complex business problems brings to you detailed insights on supply chain analytics can help address the factors impacting ventilator shortages globally.

Arizona physicians adopt CGM ELVI Telemedicine to offer virtual consultations, reduce office visits

Novo Nordisk announced that the New England Journal of Medicine published results of a phase 3 trial evaluating the investigational use of Saxenda® injection 3.0 mg in adolescents with obesity.1 The study was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting in San Francisco, Calif., and will be published in a supplemental issue of the Journal of the Endocrine Society.

Sorrento Therapeutics, Inc., announced it has entered into a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento’s COVID-19 therapeutic product candidates.

tellic, a technology startup based in New York, NY has been working for five years to develop an AI tool that surfaces actionable insights from biomedical research.

REGENXBIO grants Ultragenyx exclusive, worldwide rights to NAV AAV8 and AAV9 Vectors for the development and commercialization of gene therapy treatments for a rare metabolic disorder